Anthropic's Mithril Medicine drug programs
Anthropic's October 27 report discloses its July acquisition of Mithril Medicine and describes Claude-assisted rare-disease drug programs and six research partnerships.
What happened lately
Anthropic's Mithril Medicine drug programs timeline
Anthropic’s October 27 update describes its acquisition of Mithril Medicine, completed in July according to the accompanying case study. Founder Cody Tranbarger is continuing two rare muscular-dystrophy drug programs at Anthropic. The company says Claude helped him coordinate operations and experiments with external laboratories.
The associated October 26 technical report presents preclinical work on a bispecific bridging antibody for LAMA2-related congenital muscular dystrophy. It is explicitly not peer reviewed. The report and company update do not establish a successful human treatment; clinical trials remain a conditional future target.